Tetrahedron 66 (2010) 8522-8526

Contents lists available at ScienceDirect

Tetrahedron



journal homepage: www.elsevier.com/locate/tet

Concise and practical route to tri- and tetra-hydroxy seven-membered iminocyclitols as glycosidase inhibitors from D-(+)-glucurono- γ -lactone

Navnath B. Kalamkar^a, Vijay M. Kasture^a, Sanjay T. Chavan^b, Sushma G. Sabharwal^b, Dilip D. Dhavale^{a,*}

^a Department of Chemistry, Garware Research Centre, University of Pune, Pune 411 007, India ^b Division of Biochemistry, Department of Chemistry, University of Pune, Pune 411 007, India

ARTICLE INFO

Article history: Received 30 June 2010 Received in revised form 25 August 2010 Accepted 25 August 2010 Available online 24 September 2010

Keywords: Iminocyclitols Glucuronolactone Reductive amination Glycosidase inhibitors

ABSTRACT

An efficient and short total synthesis of tetrahydroxy-1c and trihydroxy-azepane 1d is reported in 72% and 57% overall yields, respectively, from D-(+)-glucurono- γ -lactone. Thus, D-glucuronolactone **2** on acetonide protection. DIBAL-H reduction and one-pot intermolecular reductive amination followed by -NCbz protection afforded 6-(N-benzyl-N-benzyloxycarbonyl) amino-6-deoxy-1,2-O-isopropylidene- α p-gluco-1,4-furanose 5a. 1,2-Acetonide hydrolysis in 5a and Pd-mediated intramolecular reductive aminocyclization afforded tetrahydroxyazepane 1c. An analogous pathway with 5-deoxy-1,2-O-isopropylidene- α -p-glucurono-6,3-lactone **3b** gave trihydroxy-azepane **1d**. Glycosidase inhibitory activity of **1c**/1d was studied and 1d was found to be potent inhibitor of α -mannosidase and β -galactosidase.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Iminosugars are known for their potential therapeutic applications in the treatment of cancer,¹ diabetes,² Gaucher's disease,³ and the viral infections including HIV⁴ due to their glycosidase inhibitory activity. Amongst monocyclic iminosugars⁵ the seven-membered iminocyclitols, commonly known as azaseptanoses or polyhydroxy azepanes,⁶ also demonstrate potent glycosidase⁷ and glycosyltransferase inhibitory activity.⁸ Due to flexibility of seven-membered ring (compared with five and six-membered-ring) polyhydroxylated azepanes 1 (Fig. 1) adopt different pseudo-half-chair conformations,



Fig. 1. Azepane iminocyclitols.

required to mimic the putative oxo-carbenium ion like TS with minimum energetic demand, thus favoring binding to the enzyme active site in the glycosidase process.⁹ As a result, polyhydroxylated azepanes were found to be potent glycosidase inhibitors and in some cases proven to be more active than their lower ring analogues. For example, tetrahydroxy azepane **1a** is a better inhibitor of β -*N*-acetylglucosaminidase than 1-deoxy-N-acetylnojirimycin and 1b is exhibiting higher α -mannosidase and β -galactosidase inhibitory activity than its six-membered ring analogues 1-deoxymannojirimycin and 1-deoxygalactonojirimycin, respectively.¹⁰ In addition the high water solubility and flexibility of iminocycloheptitols allow the hydroxyl groups to adopt a variety of positions increasing the probability of them forming hydrogen bonds with the purine and pyrimidine bases, hence that make them potentially useful as DNA minor groove binding ligands (MGBL's).¹¹

A number of syntheses for trihydroxy-^{12,14a} and tetrahydroxyazepanes^{13,14b,c} along with their hydroxymethyl/acetamido analogues¹⁵ are known in the literature. In general, chiron approaches to iminocycloheptitols make use of starting materials, such as chiroinositols, L-serine, D-mannitol, trans-4-hydroxy-L-proline, D-glucose, and D-quinic acid. etc., whereas, in asymmetric approaches Prinzbach et al. illustrated a cyclooctatetraene route and Mehta and Lakshminath reported a norbornyl route toward the synthesis of novel polyhydroxylated azepanes.^{15h,i} A chemo-enzymatic approach to various polyhydroxy azepanes has been reported independently by Wong and Wang groups.^{10,13d}

As a part of our ongoing efforts in syntheses and investigation of biological activity of polyhydroxy azepanes and azocanes,¹⁴ we



^{*} Corresponding author. Tel.: +91 2025691727; fax: +91 2025691728; e-mail address: ddd@chem.unipune.ac.in (D.D. Dhavale).

^{0040-4020/\$ -} see front matter © 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2010.08.060

thought of exploiting D-glucurono lactone **2** (easily available by oxidation of amylose and commercially cheap as compared to diacetone D-glucose)¹⁶ as a substrate in the synthesis of iminocyclitols **1c** and **1d**. The only one example reported, by Dax et al. using glucuronolactone derivative in the synthesis of tetrahydroxy azepane **1c** via the key step S_N2 displacement by an azide nucleophile, on 5-chloro-5-deoxy-1,2-*O*-isopropylidene- β -L-*ido*-furanose^{13h} leading to the mixture of regio-isomeric products with low yields of target molecules. Here we report the short, high yielding and stereospecific synthesis, of D-gluco-configured tetrahydroxy-**1c** and D-xylo-configured trihydroxy-azepanes **1d** from D-glucurono- γ -lactone, and evaluation of their glycosidase inhibitory activity.

2. Result and discussion

As shown in Scheme 1, D-(+)-glucurono-6,3-lactone **2** was treated with acetone and concentrated H_2SO_4 to get the 1,2-O-isopropylidene- α -D-glucofuranurono-6,3-lactone **3a** in 95% yield.¹⁷ Reaction of γ -lactone **3a** with DIBAL-H in dichloromethane at -78 °C afforded lactol **4a** that was directly (without purification) subjected to the intermolecular reductive amination with benzyl amine, acetic acid (cat.) and NaBH₃CN in methanol. The amine thus generated was treated, in the same pot, with aq sodium bicarbonate and benzyl chloroformate to give *N*-Cbz



Scheme 1. Synthesis of 1c and 1d.

protected C-6 amino compound **5a**. (88% yield in two steps after column chromatography). Finally, hydrolysis of 1,2-acetonide functionality in **5a** using TFA/water (3:2) at 25 °C furnished C-1 anomeric mixture **6a** that was directly subjected to intramolecular reductive aminocyclization using 10% Pd(OH)₂/C in aq methanol at 90 psi to afford tetrahydroxy azepane **1c** (86% in two steps) as a yellowish sticky solid. This one-pot three-step process involves hydrogenolysis of *N*-benzyl and *N*-Cbz functionalities, in situ formation of seven-membered cyclic-imine and concomitant reduction under hydrogenation conditions to give tetrahydroxy azepane **1c**. The specific rotation and spectral data of **1c** were found to be in agreement with that reported; $[\alpha]_D^{25} - 24.2$ (*c* 0.85, H₂O) [lit.^{13h} $[\alpha]_D^{20} - 23.0$ (*c* 0.85, H₂O). Treatment of **1c** with methanol-HCl afforded hydrochloride salt **1c**·**HCl** (98%) whose spectral and analytical data was also found to be in consonance with that reported.^{13h}

While targeting the synthesis of trihydroxy-azepane 1d, we were in need of 5-deoxy-1,2-O-isopropylidene-glucuronolactone. Although different methods are known for the deoxygenation of 3a to **3b**,¹⁸ we adopted one-step process reported by Rauter et al.^{18a} Thus lactone **3a** was reacted with triphenylphosphine, imidazole, and iodine at 60 °C for 3.5 h to give 5-deoxy-1,2-O-isopropylidenep-glucurono-6,3-lactone **3b** as a crystalline solid in 76% yield. Reaction of lactone **3b** with DIBAL-H in anhydrous CH₂Cl₂ at -78 °C afforded lactol 4b, as an anomeric mixture, that on reductive amination using benzyl amine and NaBH₃CN in cat acetic acid afforded amine, which was (in same pot) treated with benzyl chloroformate and an NaHCO₃ to get -NCbz protected aminol **5b** in 93% yield in two steps after column chromatography. The -NCbz protected aminol **5b** on treatment with 60% ag TFA and hydrogenation using 10% Pd(OH)₂/C in methanol/H₂O (9:1) afforded trihydroxy-azepane 1d in 85% yield in two steps. The spectral data were found to be in agreement that with reported by us and 'that with its enatiomer'.^{12b,14a} The hydrochloride salt of **1d** is not known, therefore we treated 1d with methanol/HCl that afforded hydrochloride salt 1d · HCl in 98% yield whose spectral and analytical data were found to be in agreement with the structure.

2.1. Biological evaluation

Iminocyclitols **1c** and **1d** thus obtained as free bases were tested for their inhibitory activity against various glycosidases namely α -galactosidase, β -galactosidase, β -glucosidase, α -mannosidase, *N*-acetyl- β -glucosaminidase (all isolated from almond seeds), α -galactosidase (from *Geobacillus toebii* BK1), and α -glucosidase (from Baker's yeast-Sigma Chemical Co.). Thus, tetrahydroxy azepane **1c** showed a strong inhibitoin against α -galactosidase (K_i =5 µM) isolated from the green coffee beans.¹⁰ Inhibition against β -glucosidase (inhibition=9%) isolated from almond seeds and α glucosidase (inhibition=21%) from bakers yeast was insignificant¹⁰ while, no significant inhibition was observed for **1c** against the other enzymes studied. Trihydroxy-azepane **1d** was found to be a potent competitive inhibitor of α -mannosidase and β -

Table 1	
Glycosidase inhibition study of 1d (as free base	:) ^{a,b}

Enzyme	IC ₅₀	Ki
α-Galactosidase	NI	NI
β-Galactosidase	147	161
α-Glucosidase	NI	NI
β-Glucosidase	142	485
α-Mannosidase	775	100
N-Acetyl-β-glucosaminidase	NI	NI
α-Galactosidase	NI	NI
(G. toehii BK1)		

(0. 100011 DK1)

^a IC₅₀ and K_i Values are in μ M.

^b NI=No inhibition at 1 mM concentration of Inhibitor.

galactosidase with K_i values of 100 and 161 µM, respectively (Table 1). Compound **1d** also showed moderate inhibition against β-glucosidase (K_i =485 µM and IC₅₀=142 µM) and was noticed to be a better inhibitor of β-glucosidase than its enantiomer **1e** (IC₅₀=250 µM)^{12b} and its C2 epimer **1f**^{12c} (Fig. 1).

3. Conclusions

In summary, we have developed a new, short, and straightforward total synthesis of tetrahydroxy-1c and trihydroxy-azepanes 1d starting from readily available and cheap D-(+)-glucurono- γ -lactone in five and six steps in overall 72% and 57% yields, respectively. The practicability of our method lies with the fact that: (a) apart from protection and de-protection steps (three) the other two steps involve routine reactions such as DIBAL-H reduction, reductive amination and hydrogenation (b) column chromatography was applied at only two stages-one for the purification of *N*-Cbz aminol compounds **5a/5b** and other for the purification of iminocyclitols **1c/1d** thus making the synthetic route workable on multigram scale. From the literature values of other iminosugars,^{12b,c} it is better to say that trihydroxy-azepane **1d** showed moderate to weak inhibitory properties against α mannosidase, β -galactosidase and β -glucosidase. The methodology could be further extended in the syntheses of different other iminosugars and polyhydroxylated azepanes, using other readily available sugar γ -lactones,¹⁹ and work in this direction is in progress.

4. Experimental

4.1. General methods

Melting points were recorded with Thomas Hoover Capillary melting point apparatus and are uncorrected. IR spectra were recorded with Shimadzu FTIR-8400 as a thin film or in Nujol mull or using KBr pellets and are expressed in cm⁻¹. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra were recorded with Varian Mercury instrument using CDCl₃, D₂O or CD₃OD as a solvent. Elemental analyses were carried out with Thermo-Electron Corporation CHNS analyzer Flash-EA 1112 at Department of Chemistry, University of Pune, Pune. Optical rotations were measured using Bellingham Stanley-ADP 220 digital polarimeter with sodium light (589.3 nm) at 25 °C. Thin layer chromatography was performed on pre-coated plates (0.25 mm, silica gel 60 F₂₅₄). Visualization was made by absorption of UV light or by thermal development after spraying with 3.5% solution of 2,4-dinitrophenylhydrazine in ethanol/H₂SO₄ and with basic aqueous potassium permanganate solution. Column chromatography was carried out with silica gel (100–200 mesh). Unless not mention the reactions were carried out in oven-dried glasswares under dry N2. Acetone, dichloromethane, toluene, and methanol were purified and dried before use. Distilled *n*-hexane, ethyl acetate, CH₂Cl₂, and methanol were used for column chromatography. After decomposition of the reaction with water, the work-up involves washing of combined organic layer with water, brine, drying over anhydrous sodium sulfate, and evaporation of solvent at reduced pressure using rotary evaporator.

4.1.1. 1,2-O-Isopropylidene- α -D-glucofuranurono-6,3-lactone (**2**). It was prepared by the slightly modified procedure of Klemer et al.¹⁷ To a stirred suspension of α -D-glucurono- γ -lactone (20.0 g, 0.17 mmol) in dry acetone (500 mL) concentrated sulfuric acid (10 mL) was added drop wise over the period of 20 min at room temperature, the reaction mixture was then vigorously stirred for further 4 h. The resulting clear yellow solution was neutralized with slow of addition of solid sodium carbonate (27 g). Solution was

filtered through Celite and residue washed with acetone (200 mL×3) the combine filtrate was concentrated, dissolved in chloroform (500 mL), and washed with water (100 mL). Organic layer was dried on sodium sulfate and concentrated under vacuum, the residue was recrystallised (CHCl₃/*n*-hexane) to give **2** (23.54 g) as white solid, mp 119–121 °C [lit.¹⁷ 119–120 °C]; [α]_D²⁵ 52.0 (*c* 1.95, CHCl₃) [lit.¹⁷ [α]_D²⁰ 52.5 (*c* 1.95, CHCl₃)].

4.1.2. 1,2-O-Isopropylidene-6-(N-benzyl,N-benzyloxycarbonyl) amino-6-deoxy- α -D-gluco-1,4-furanose (**5a**). To a cooled solution of **3a** (2 g, 9.25 mmol) in dry CH_2Cl_2 (100 mL) at -78 °C was added 1 M solution of DIBAL-H in toluene (10.12 mL, 10.18 mmol). After stirring for 0.5 h at -78 °C, reaction mixture was quenched by aq ammonium chloride (20 mL) and stirred for 2 h at 0 °C. The solution was filtered through Celite, and residue was washed with dichloromethane (20 mL×4). Evaporation of solvent under reduced pressure afforded lactol 4a (1.93 g, 96% crude yield) as a sticky solid. To the solution of crude lactol 4a (1.71 g) at -20° C in dry methanol (15 mL) was added an ice cold solution of benzyl amine (0.94 mL, 8.62 mmol) and glacial acetic acid (0.07 mL 1.17 mmol) in dry methanol (2 mL) over a period of 10 min and solution was stirred at -20 °C for 1 h. Sodium cyanoborohydride (1.21 g, 19.61 mmol) was added in three portions (20 min) at -20 °C, and the solution was warmed to 0 °C and stirred for 2 h. To the above ice cold solution was added aq NaHCO₃ (3.29 g, 39.15 mmol in 10 mL water) followed by addition of 50% solution of benzyl chloroformate in toluene (3.95 mL 23.5 mmol). The reaction mixture was allowed to attain room temperature and stirred for 3 h. Methanol was evaporated under reduced pressure and the residue was extracted with chloroform (25 mL×3). The combined organic layer was dried (Na₂SO₄) and concentrated. Purification by column chromatography using *n*-hexane/ethyl acetate=7/3 gave 5a (3.19 g, 88% over two steps) as a colorless sticky solid. Found: C, 65.15; H, 6.70. C₂₄H₂₉NO₇ requires: C, 65.00; H, 6.59; R_f 0.40 (*n*-hexane/ethyl acetate=1/1); $[\alpha]_D^{25}$ -1.2 (*c* 4.68, CHCl₃); IR (CH₂Cl₂) 3429 (broad), 1678, 1244, 1076 cm⁻¹; ¹H NMR 300 MHz (CDCl₃+D₂O) δ 1.25 (3H, s, CH₃), 1.42 (3H, s, CH₃), 3.41-3.60 (2H, br s, N-CH₂Ph), 3.97 (1H, dd, J=5.7 and 1.5 Hz, H-4), 4.00-4.10 (1H, m, H-5), 4.32 (1H, br s, H-3), 4.46 (1H, d, J=3.5Hz, H-2), 4.54 (1H, br s, 6-H), 4.62-4.70 (1H, m, 6-H), 5.16 (2H, s, O-CH₂Ph) 5.94 (1H, d, J=3.5Hz, H-1), 7.02-7.42 (10H, m, Ar–H); ¹³C NMR (75 MHz, CDCl₃) δ 26.1 (CH₃), 26.8 (CH₃), 51.7 (C-6), 52.1 (N-CH₂Ph), 68.0 (O-CH₂Ph) 70.4 (C-5), 75.1, 80.6, 85.1 (C-2, C-3, C-4), 105.1 (C-1), 111.6 (isopropylidene), 127.4, 127.5, 127.9, 128.2, 128.5, 128.6, 130.9, 140.0 (Ar), 159.0 (NCOO).²⁰

4.1.3. 1,6-Dideoxy-1,6-imino-D-glucitol (**1c**). A solution of **5a** (0.43 g, 2.63 mmol) in TFA/H₂O (3:2, 8 mL) was stirred at 0 °C for 30 min and at 25 °C for 4 h. Solvent was co-evaporated with toluene at rotary evaporator using high vacuum to furnish sticky solid. A solution of the above product and 10% Pd(OH)₂/C (0.06 g) in aq methanol (5 mL, 9:1) was hydrogenated at 90 psi for 48 h at 25 °C. The catalyst was filtered through Celite and solvent was evaporated to afford thick liquid. Purification by column chromatography (CH₂Cl₂/MeOH/25% NH₄OH=2/2/0.2) yielded **1c** (136 mg, 86%) as a semi solid: $R_f 0.4$ (CH₂Cl₂/MeOH/25% NH₄OH=2/7/1); $[\alpha]_D^{25}$ –24.2 (*c* 0.85, H₂O) [lit.^{13h} $[\alpha]_D^{20}$ –23.0 (*c* 0.85, H₂O).

4.1.4. 1,6-Dideoxy-1,6-imino-*D*-glucitol, hydrochloride salt (**1c** +**HCl**). To an ice cold solution of **1c** (15 mg, 0.092 mmol) in methanol (1 mL) was added concentrated HCl (0.1 mL) and the reaction mixture was stirred at 25 °C for 12 h. The solvent was evaporated to dryness and the residue was dissolved in distilled water (1 mL) and extracted with chloroform (1 mL×3). The aqueous layer was concentrated to afford hydrochloride salt of **1c** (17 mg, 98%) as a gummy solid. Found: C, 36.40; H, 7.35. C₆H₁₄ClNO₄ requires: C,

36.10; H, 7.07; R_f 0.3 (CH₂Cl₂/MeOH/25% NH₄OH=2/7/1); $[\alpha]_D^{25}$ -12.6 (*c* 1.3, MeOH) [lit.^{13f} $[\alpha]_D^{26}$ -15.0 (*c* 1, H₂O)].

4.1.5. 5,6-Dideoxy-6-(N-benzyl,N-benzyloxycarbonyl)amino-1,2-0isopropylidene- α -D-gluco-1,4-furanose (5b). Reaction of 3b (1.7 g, 8.5 mmol) in dry CH₂Cl₂ (90 mL) with 1 M solution of DIBAL-H in toluene (9.33 mL, 9.35 mmol) as stated for 4a furnished lactol 4b (1.66 g. 97% crude vield) as a sticky solid. Reaction of **4b** (1.2 g 5.94 mmol) with benzyl amine (0.71 mL, 6.53 mmol), sodium cyanoborohydride (0.92 g, 14.8 mmol) and glacial acetic acid (0.05 mL 0.9 mmol) in dry methanol (2 mL) followed by reaction with benzyl chloroformate in toluene (2.98 mL 17.81 mmol) and aq NaHCO3 (2.5 g, 29.7 mmol, 8 mL water) as described for 5a and column chromatography using *n*-hexane/ethyl acetate=4/1 yielded **5b** (2.43 g, 92% in two steps) as a colorless thick liquid. Found: C, 67.21; H, 7.12. C₂₄H₂₉NO₆ requires: C, 67.43; H, 6.84; R_f0.56 (*n*-hexane/ethyl acetate=1/1); $[\alpha]_D^{25}$ -2.3 (*c* 2.54, CHCl₃); IR (CH₂Cl₂) 3443 (broad), 1693, 1220, 1076 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.29 (3H, s, CH₃), 1.45 (3H, s, CH₃), 1.54-2.0 (2H, m, H-5), 3.10-3.40 (2H, m, H-6), 3.80-4.20 (3H, m, H-3, H-4, OH), 4.38-4.6 (3H, m, N-CH₂Ph, H-2), 5.20 (2H, s, O-CH₂Ph), 5.82 (1H, d, J=3.57, 1-H), 7.10-7.40 (10H, m, Ar-H); ¹³C NMR (75 MHz, CDCl₃) δ 26.0 (CH₃), 26.5 (CH₃), 43.5 (C-5), 44.0 (C-6) 50.7 (N-CH2Ph), 67.3 (O-CH2Ph) 74.9 (C-4), 78.0 (C-3), 85.1 (C-2), 104.2 (C-1), 111.1 (isopropylidene), 127.3, 127.7, 127.9, 128.3, 128.4, 136.2, 137.3 (Ar), 156.4 (NCOO).²¹

4.1.6. 1,5,6-*Trideoxy*-1,6-*imino*-*D*-*xylo*-*hexitol* (**1d**). Reaction of **5b** (0.61 g, 1.42 mmol) with TFA/H₂O (3:2, 12 mL) followed by hydrogenation with 10% Pd(OH)₂/C (0.08 g) in aq methanol (10 mL, 9:1) as described for **1c** and column chromatography purification using CH₂Cl₂/MeOH/25% NH₄OH 3/2/0.2 afforded **1d** (178 mg, 85%) as a sticky solid: R_f 0.4 (CH₂Cl₂/MeOH/25% NH₄OH=3/6/1); $[\alpha]_D^{25}$ 18.1 (*c* 0.95, MeOH) [lit.^{14a} $[\alpha]_D^{26}$ 16.36 (*c* 0.33, MeOH)].

4.1.7. 1,5,6-Trideoxy-1,6-imino-*p*-xylo-hexitol, hydrochloride salt (**1d** · **HCl**). Compound **1d** (40 mg, 0.27 mmol) in methanol (3 mL) was reacted with concentrated HCl (0.3 mL) as described for **1c** · **HCl** to afford hydrochloride salt **1d** · **HCl** (49 mg, 99%) as a yellow gummy solid. Found: C, 39.53; H, 7.91. C₆H₁₄ClNO₃ requires C, 39.24; H, 7.68; *R*_f 0.3 (CH₂Cl₂/MeOH/25% NH₄OH=2/6/1); $[\alpha]_{D}^{2}$ 4.0 (c 2.4, H₂O). IR (KBr) 3331–2833 (broad), 1579, 1053 cm⁻¹; ¹H NMR (300 MHz, D₂O) δ 2.12–2.25 (2H, m, H-5), 3.16–3.30 (1H, m, H-6), 3.32–3.58 (3H, m, H-1/H-6), 3.68 (1H, dd, *J*=7.2 and 5.2 Hz, H-3), 3.84 (1H, dt, *J*=7.2 and 3.6 Hz, H-4), 4.10 (1H, dt, *J*=5.2 and 2.3 Hz, H-2); ¹³C NMR (75 MHz, D₂O) δ 27.6 (C-5), 42.2 (C-6), 45.3 (C-1) 68.2 (C-4), 72.5 (C-2), 78.4 (C-3).

4.2. Procedure for the inhibition assay

The enzymes α -galactosidase, β -galactosidase, β -glucosidase, α mannosidase, and N-acetyl-B-D-glucosaminidase were isolated from almond seeds; α-galactosidase was isolated from G. toebii BK1 and α -glucosidase was procured from Sigma Chemical Co. were used for glycosidase inhibitory activity. Inhibition potencies of 1c and 1d were determined by measuring the residual hydrolytic activities of the glycosidases. The substrates p-nitrophenyl- β -D-glucopyranoside, *p*-nitrophenyl- α -D-glucopyranoside, *p*-nitrophenyl- α -D-galactopyranoside and p-nitrophenyl- β -D-galactopyranoside, *p*-nitrophenyl-*N*-acetyl-β-D-glucopyranoside, and *p*-nitrophenyl-α-D-mannopyranoside (all of Sigma Chemicals Co., USA) of 2 mM concentration, were prepared in 0.025 M citrate buffer with pH 4.0 and used for assay. The test compound (of various concentrations from 20 μ M to 1000 μ M) was pre-incubated with the enzyme, buffered at its optimal pH, for 1 h at 37 °C. The enzyme reaction was initiated by the addition of 100 μL of substrate. Reaction was terminated at the end of 90 min by the addition of 0.05 M borate buffer (pH 9.8) and absorbance of the liberated *p*-nitrophenol was measured at 405 nm with a UV–visible Spectrophotometer. Controls were run simultaneously in the absence of test compound. One unit of glycosidase activity is defined as the amount of enzyme that hydrolyzed 1 μ mol of *p*-nitrophenol per minute at 37 °C. The inhibition constants (*K*_i) and the nature of the inhibition were determined from Lineweaver–Burk plots.

Acknowledgements

We are grateful to Prof. M.S. Wadia for helpful discussions. We are thankful to the University of Pune for financial support (BCUD/ OSD/184-2009). N.B.K. and V.M.K. are thankful to the CSIR, New Delhi, for Senior Research Fellowships.

Supplementary data

Copies of ¹H and ¹³C NMR spectra of **5a**, **5b**, **1c**, **1c** · **HCl**, **1d**, **1d** · **HCl** and Lineweaver–Burk plots of **1d** against glycosidase. Supplementary data associated with this article can be found in online version at doi:10.1016/j.tet.2010.08.060. These data include MOL files and InChIKeys of the most important compounds described in this article.

References and notes

- (a) Woynaroska, B.; Wilkiel, H.; Sharma, M.; Carpenter, N.; Fleet, G. W. J.; Bernacki, R. J. *Anticancer Res.* **1992**, *12*, 161; (b) Gross, P. E.; Baker, M. A.; Carver, J. P.; Dennis, J. W. *Clin. Cancer Res.* **1995**, *1*, 935.
- (a) Johnston, P. S.; Coniff, R. F.; Hoogwerf, B. J.; Santiago, J. V.; Pi-Sunyer, F. X.; Krol, A. Diabetes Care 1994, 17, 20; (b) Kleist, P.; Ehrlich, A.; Suzuki, Y.; Timmer, W.; Wetzelsberger, N.; Luecker, P. W.; Fuder, H. Eur. J. Clin. Pharmacol. 1997, 53, 149.
- (a) Alper, J. Science 2001, 291, 2338; (b) Stone, D. L.; Tayebi, N.; Orvisky, E. Hum. Mutat. 2000, 15, 181.
- (a) Robina, I.; Moreno-Vargas, A. J.; Carmona, A. T.; Vogel, P. Curr. Drug Metab. 2004, 5, 329; (b) Fleet, G. W. J.; Karpas, A.; Dwek, R. A.; Fellows, L. E.; Tyms, A. S.; Petursson, S.; Namgoong, S. K.; Ramsden, N. G.; Smith, P. W.; Son, J. C.; Wilson, F.; Witty, D. R.; Jacobs, G. S.; Rademacher, T. W. *FEBS Lett.* 1988, 237, 128.
- (a) Stutz, A. E. Iminosugars as Glycosidase Inhibitors: Nojirimycin and Beyond, 1st ed.; Wiley: Weinheim, Germany, 1999; (b) Iminosugars: From Synthesis to Therapeutic Applications; Compain, P., Martin, O. R., Eds.; John Wiley: Chichester, UK, 2007; (c) Paulsen, H. Angew. Chem., Int. Ed. Engl. 1966, 5, 495; (d) Look, G. C.; Fotsch, C. H.; Wong, C.-H. Acc. Chem. Res. 1993, 26, 182; (e) Ganem, B. Acc. Chem. Res. 1996, 29, 340; (f) de Melo, E. B.; Gomes, A. d. S.; Carvalho, I. Tetrahedron 2006, 62, 10277; (g) Pandey, G.; Dumbre, S. G.; Khan, M. I.; Shabab, M. J. Org. Chem. 2006, 71, 8481; (h) Davis, B. G. Tetrahedron: Asymmetry 2009, 20, 652.
- 6. Paulsen, H.; Todt, K. Chem. Ber. 1967, 100, 512.
- (a) Simmott, M. L. Chem. Rev. **1990**, 90, 1171; (b) Winchester, B.; Fleet, G. W. J. Glycobiology **1992**, 2, 199; (c) Bols, M. Acc. Chem. Res. **1998**, 31, 1; (d) Heightman, T. D.; Vasella, A. T. Angew. Chem., Int. Ed. **1999**, 38, 750; (e) Zechel, D. L.; Withers, S. G. Acc. Chem. Res. **2000**, 33, 11; (f) Lillelund, V. H.; Jensen, H. H.; Liang, X.; Bols, M. Chem. Rev. **2002**, 102, 515; (g) Asano, N. Curr. Top. Med. Chem. **2003**, 3, 471.
- (a) Kim, Y. J.; Ichikawa, M.; Ichikawa, Y. J. Am. Chem. Soc. 1999, 121, 5829; (b) Sears, P.; Wong, C.-H. Angew. Chem., Int. Ed. 1999, 38, 2301; (c) Saotome, C.; Wong, C.-H.; Kanie, O. Chem. Biol. 2001, 8, 1061; (d) Pandey, G.; Kapur, M. Org. Lett. 2002, 4, 3883; (e) Compain, P.; Martin, O. R. Curr. Top. Med. Chem. 2003, 3, 541.
- Qian, X.-H.; Moris-Varas, F.; Wong, C.-H. *Bioorg. Med. Chem. Lett.* **1996**, 6, 1117.
 Our results are well in agreement with that reported see: Moris-Varas, F.; Qian, X.-H.; Wong, C.-H. *J. Am. Chem. Soc.* **1996**, *118*, 7647.
- 11. Johnson, H. A.; Thomas, N. R. Bioorg. Med. Chem. Lett. 2002, 12, 237.
- 12. For trihydroxy azepane 1d and stereoisomers see: (a) Shih, T.-L.; Yang, R.-Y.; Li, S.-T.; Chiang, C.-F.; Lin, C.-H. J. Org. Chem. 2007, 72, 4258; (b) Moutel, S.; Shipman, M.; Martin, O. R.; Ikeda, K.; Asano, N. Tetrahedron: Asymmetry 2005, 16, 487; (c) Andersen, S. M.; Ekhart, C.; Lundt, I.; Stutz, A. E. Carbohydr. Res. 2000, 326, 22; (d) Gallos, J. K.; Demeroudi, S. C.; Stathopoulou, C. C.; Dellios, C. C. Tetrahedron Lett. 2001, 42, 7497; (e) See Ref. 6. This paper does not describe the synthesis of the free azepane base but the protected version: N-Ac, tri-O-Ac derivative.
- For tetrahydroxy azepane 1c and stereoisomers see: (a) Ref. 10. (b) Painter, G. F.; Eldridge, P. J.; Falshaw, A. Bioorg. Med. Chem. 2004, 12, 225; (c) Painter, G. F.; Falshaw, A.; Wong, H. Org. Biomol. Chem. 2004, 2, 1007; (d) Andreana, P. R.; Sanders, T.; Janczuk, A.; Warrick, J. I.; Wang, P. G. Tetrahedron Lett. 2002, 43, 6525; (e) Fuentes, J.; Gasch, C.; Olano, D.; Pradera, M. A.; Repetto, G.; Sayago, F. J. Tetrahedron: Asymmetry 2002, 13, 1743; (f) Joseph, C. C.; Regeling, H.; Zwanenburg, B.; Chittenden, G. J. F. Tetrahedron 2002, 58, 6907; (g) Painter, G. F.; Falshaw, A. J. Chem. Soc., Perkin Trans. 1 2000, 1157; (h) Dax, R.; Gaigg, B.; Grassberger, B.; Koelblinger, B.; Stutz, A. E. J. Carbohydr. Chem. 1990, 9, 479; (i) Fuentes, J.; Gasch, C.; Olano, D.; Pradera, M. A. Tetrahedron Lett. 1999, 40, 4063;

(j) Gauzy, L; Merrer, Y. L; Depezay, J.-C. Tetrahedron Lett. **1999**, 40, 6005; (k) Merrer, Y. L; Poitout, L; Depezay, J.-C.; Dosbaa, I.; Geoffroy, S.; Foglietti, M.-J. Bioorg. Med. Chem. Lett. **1997**, 5, 519; (l) Qian, X.; Moris-Varas, F.; Fitzgerald, M. C.; Wong, C.-H. Bioorg. Med. Chem. **1996**, 4, 2055; (m) Lohray, B. B.; Jayamma, Y.; Chatterjee, M. J. Org. Chem. **1995**, 60, 5958; (n) Poitout, L; Merrer, Y. L; Depezay, J.-C. Tetrahedron Lett. **1994**, 35, 3293; (o) Farr, R. A.; Holland, A. K.; Huber, E. W.; Peet, N. P; Weintraub, P. M. Tetrahedron **1994**, 50, 1033; (p) Bernotas, R. C; Ganem, B. Tetrahedron Lett. **1984**, 25, 165.

- 14. For synthesis of 1c and 1d from our group see: (a) Dhavale, D. D.; Chaudhari, V. D.; Tilekar, J. N. *Tetrahedron Lett.* 2003, 44, 7321; (b) Tilekar, J. N.; Patil, N. T.; Jadhav, H. S.; Dhavale, D. D. *Tetrahedron* 2003, 59, 1873; (c) For our recent reports on azepane and other iminosugars see: Jadhav, V. H.; Bande, O. P.; Puranik, V. G.; Dhavale, D. D. *Tetrahedron* 2010, 66, 2830; (d) Jadhav, V. H.; Bande, O. P.; Puranik, V. G.; Dhavale, D. D. *Tetrahedron* 2010, 66, 2830; (d) Jadhav, V. H.; Bande, O. P.; Puranik, V. G.; Dhavale, D. D. *Tetrahedron*: Asymmetry 2010, 21, 163; (e) Kalamkar, N. B.; Kasture, V. M.; Dhavale, D. D. *J. Org. Chem.* 2008, 73, 3619; (f) Dhavale, D. D.; Markad, S. D.; Karanjule, N. S.; Reddy, P. J. *J. Org. Chem.* 2004, 69, 4760 and references cited therein.
- For recent literature on hydroxy methyl/actamido analogues of azepanes see:

 (a) Estevez, A. M.; Soengas, R. G.; Otero, J. M.; Estevez, J. C.; Nash, R. J.; Estevez, R. J. *Tetrahedron: Asymmetry* **2010**, *21*, 21; (b) Marcelo, F.; He, Y.; Yuzwa, S. A.; Nieto, L.; Jimećnez-Barbero, J.; Sollogoub, M.; Vocadlo, D. J.; Davies, G. D.; Blećriot, Y. J. Am. Chem. Soc. **2009**, *131*, 5390; (c) Li, H.; Marcelo, F.; Bello, C.; Vogel, P.; Butters, T. D.; Rauter, A. P.; Zhang, Y.; Sollogoub, M.; Yves, B. Bioorg. *Med. Chem. Lett.* **2009**, *17*, 5598; (d) Li, H.; Zhang, Y.; Vogel, P.; Sinay, P.; Bleriot, Y. *Chem. Commun.* **2007**, 183; (e) Chang, M.-Y.; Kung, Y.-H.; Ma, C.-C.; Chen, S.-T. *Tetrahedron* **2007**, 63, 1339; (f) Lin, C.-C.; Pan, Y.-S.; Patkar, L. N.; Lin, H.-M.;

Tzou, D.-L. M.; Subramanian, T.; Lin, C.-C. *Bioorg. Med. Chem.* **2004**, *12*, 3259; (g) Assiego, C.; Pino-Gonzalez, M. S.; Lopez-Herrera, F. J. *Tetrahedron Lett.* **2004**, *45*, 2611; (h) Armbruster, J.; Stelzer, F.; Landenberger, P.; Wieber, C.; Hunkler, D.; Keller, M.; Prinzbach, H. *Tetrahedron Lett.* **2000**, *41*, 5483; (i) Mehta, G.; Lakshminath, S. *Tetrahedron Lett.* **2002**, *43*, 331 and references cited theirin.

- 16. Cost of D-glucuronolactone is 100 g=\$ 42.0 and that of diacetone D-glucose is 25 g=~ \$ 25.6 see: Aldrich Chemistry, Handbook of Fine Chemicals; Aldrich Chemical: Milwaukee, WI, 2009–2010; pp 1084 and 1478.
- 17. Klemer, A.; Hofmeister, U.; Lemmes, R. *Carbohydr. Res.* **1979**, 68, 391.
- (a) Rauter, A. P.; Fernandes, A. C.; Figueiredo, J. A. J. Carbohydr. Chem. **1998**, *17*, 1037; (b) Matsuura, D.; Takabe, K.; Yoda, H. *Tetrahedron Lett.* **2006**, *47*, 1371.
- For other sugar γ-lactones see: (a) Csuk, R.; Hönig, H.; Nimp, J.; Weidmann, H. Tetrahedron Lett. **1980**, *21*, 2135; (b) Martin, A.; Watterson, M. P.; Brown, A. R.; Imtiaz, F.; Winchester, B. G.; Watkin, D. J.; Fleet, G. W. J. Tetrahedron: Asymmetry **1999**, *10*, 355; (c) Weymouth-Wilson, A. C.; Clarkson, R. A.; Jones, N. A.; Best, D.; Wilson, F. X.; Pino-Gonzalez, M.-S.; Fleet, G. W. J. Tetrahedron Lett. **2009**, *50*, 6307.
- 20. The ¹H and ¹³C NMR spectra of **5a** and **5b** showed additional signals >10% due to the isomerization by restricted rotation around C–N. see: In *Applications of NMR Spectroscopy in Organic Chemistry*; Jackman, L. M., Sternhell, S., Eds.; Pergamon: Elmsford, NY, 1978; p 361.
- 21. The ¹H and ¹³C NMR spectra of **5b** showed additional signals >10% due to the isomerization by restricted rotation around C–N. see: In *Applications of NMR Spectroscopy in Organic Chemistry*; Jackman, L. M., Sternhell, S., Eds.; Pergamon: Elmsford, NY, 1978; p 361.